<DOC>
	<DOCNO>NCT02471651</DOCNO>
	<brief_summary>Laser photocoagulation intravitreal anti-vascular growth factor injection commonly use treatment option individual diabetic macular edema . However , patient continue experience persistent diabetic macular edema poor vision despite continue laser and/or anti-vegf therapy . Recent clinical trial suggest due inflammatory mediator dexamethasone intravitreal implant ( 0.7mg ) may good alternative therapy individual unresponsive laser photocoagulation intravitreal anti-vascular growth factor injection . The purpose research study compare effectiveness use dexamethasone steroid implant versus monthly intravitreal anti-VEGF injection research participant persistent diabetic macular edema ( DME ) .</brief_summary>
	<brief_title>Dexamethasone Intravitreal Implant Treatment Persistent Diabetic Macular Edema</brief_title>
	<detailed_description>Macular edema major cause central vision loss patient present diabetic retinopathy . Diabetic macular edema ( DME ) occur fluid leak center macula , part eye sharp , straight-ahead vision occur . The fluid make macula swell , blur vision . Diabetic macular edema ( DME ) affect 8 % 10 % 23.6 million diabetic individual United States . The prevalence diabetic macular edema 15 year know diabetes approximately 20 % patient type 1 diabetes , 25 % patient type 2 diabetes take insulin , 14 % patient type 2 diabetes take insulin . Within two year diagnosis , nearly half individual DME lose 2 line visual acuity ( small line read standardized vision chart hold 20 foot away ) . Diabetic macular edema typically treat laser and/or intravitreal injection drug anti-VEGF agent . Anti-VEGF agent block protein slow growth abnormal blood vessel . Dexamethasone corticosteroid use treat inflammation . Dexamethasone implant steroid implant inject eye treat swell may occur blockage certain blood vessel eye . Both anti-VEGF agent dexamethasone implant approve FDA treat DME . The purpose research study compare effectiveness use dexamethasone steroid implant versus monthly intravitreal anti-VEGF injection research participant persistent diabetic macular edema ( DME ) .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Able provide write informed consent comply study assessment full duration study . Age â‰¥ 18 year Diagnosis diabetes mellitus ( type 1 2 ) Any one following consider sufficient evidence diabetes present : Current regular use insulin treatment diabetes Current regular use oral antihyperglycemia agent treatment diabetes Clinical evidence retinal thickening due macular edema involve center macula associate diabetic retinopathy . Previous history antivegf treatment diabetic macular edema ( DME ) document incomplete resolution central subfield thicken spectraldomain optical coherence tomography ( SDOCT ) . At least 4 intravitreal antivegf injection within past six month prior baseline study visit require eligibility . Central diabetic macular edema present clinical examination SDOCT test central 1 mm subfield thickness great 300 micron measure SDOCT baseline visit . Visual acuity score great equal 19 letter ( 20/400 ) less equal 74 letter ( 20/32 ) ETDRS visual acuity protocol . Media clarity , pupillary dilation patient cooperation sufficient allow SDOCT test retinal photography . Pregnancy ( positive pregnancy test ) know pregnant ; also premenopausal woman use adequate contraception . Participation another ocular investigation trial simultaneously Blood pressure &gt; 180/110 mmHg ( systolic 180 OR diastolic 110 mmHg ) Any condition , opinion investigator , would preclude participation study ( e.g . chronic alcoholism , drug abuse ) Evidence vitreoretinal interface abnormality ocular exam OCT may contribute macular edema An eye , investigator 's opinion , chance improve visual acuity follow resolution macular edema ( e.g . presence subretinal fibrosis geographic atrophy ) Presence another ocular condition may affect visual acuity macular edema course study ( e.g . AMD , uveitis , IrvineGass ) Evidence active neovascularization iris retina Evidence central atrophy fibrosis study eye Presence substantial cataract , one might decrease vision 3 line vision sometime study . History vitreous surgery study eye History cataract surgery within 3 month enrollment . History YAG capsulotomy within 2 month enrollment . Visual acuity &lt; 20/400 ETDRS visual acuity chart fellow eye Uncontrolled glaucoma ( pressure &gt; 30 mmHg ) despite treatment glaucoma medication . History cerebral vascular accident myocardial infarction within 3 month prior Day 0 . Use systemic steroid ( eg , oral , intravenous , intramuscular , epidural , rectal , extensive dermal ) within one month prior baseline study visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>